Associate Vice President - Neurodegenerative Disease Early Phase Clinical Development @ Eli Lilly and Company
5 free lookup(s). No credit card required.
Keith Mayl Location
United Kingdom
Keith Mayl Work
2026 -
now Associate Vice President - Neurodegenerative Disease Early Phase Clinical Development @ Eli Lilly and Company
2025 -
2026 Senior Medical Director, Clinical Development, Global ALS Indication Lead @
2024 -
2025 Senior Clinical Development Lead in Neurology @
2022 -
2024 Clinical Development Lead in Neurology @
2019 -
2022 Clinical Research Physician in Neurology | Doctoral Researcher in Gene Therapy @
2019 -
2022 Honorary Specialist Registrar in Neurology @
2018 -
2019 Clinical Fellow in Neurology @
2017 -
2018 Foundation Doctor @
2016 -
2017 Foundation Doctor @
Keith Mayl Education
King's College London
Doctor of Philosophy (Clinical Neuroscience)
2019
-
2024
University of Malta
Doctor of Medicine - MD (Medicine)
2011
-
2016
Keith Mayl Summary
Keith Mayl, based in United Kingdom, is currently a Associate Vice President - Neurodegenerative Disease Early Phase Clinical Development at Eli Lilly and Company. Keith Mayl brings experience from previous roles at argenx, Servier and King's College London. Keith Mayl holds a 2019 - 2024 Doctor of Philosophy in Clinical Neuroscience @ King's College London. Keith Mayl has 1 emails on RocketReach.
Get contact details of over 700M profiles across 60M companies - all with industry-leading accuracy. Sales and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.